Zacks Research Has Bullish Forecast for PBH Q4 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Equities research analysts at Zacks Research lifted their Q4 2025 earnings per share estimates for shares of Prestige Consumer Healthcare in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.28 for the quarter, up from their prior forecast of $1.24. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q2 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.25 EPS, FY2026 earnings at $4.74 EPS and FY2027 earnings at $4.96 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the previous year, the firm posted $1.07 earnings per share. Prestige Consumer Healthcare's revenue was down .9% compared to the same quarter last year.

PBH has been the topic of several other reports. Jefferies Financial Group reiterated a "hold" rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reissued a "buy" rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Prestige Consumer Healthcare Stock Performance

PBH stock traded up $0.22 during midday trading on Monday, hitting $84.99. The stock had a trading volume of 292,955 shares, compared to its average volume of 251,520. The firm has a market capitalization of $4.20 billion, a price-to-earnings ratio of 20.63, a P/E/G ratio of 2.38 and a beta of 0.47. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a 50-day simple moving average of $75.41 and a 200 day simple moving average of $71.19. Prestige Consumer Healthcare has a 52 week low of $57.95 and a 52 week high of $86.36.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBH. Tidal Investments LLC raised its holdings in Prestige Consumer Healthcare by 4.7% during the first quarter. Tidal Investments LLC now owns 5,748 shares of the company's stock worth $417,000 after acquiring an additional 256 shares in the last quarter. Atria Investments Inc acquired a new position in shares of Prestige Consumer Healthcare in the first quarter valued at approximately $1,246,000. EverSource Wealth Advisors LLC increased its position in Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after buying an additional 208 shares during the period. GAMMA Investing LLC raised its stake in Prestige Consumer Healthcare by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 776 shares of the company's stock worth $53,000 after purchasing an additional 263 shares in the last quarter. Finally, Trust Co. of Vermont raised its position in shares of Prestige Consumer Healthcare by 18.5% in the second quarter. Trust Co. of Vermont now owns 11,022 shares of the company's stock valued at $759,000 after buying an additional 1,721 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.